Demonstrated statistical significance on regulatory co-primary endpoints of pain freedom (p
Axsome Therapeutics Announces AXS-07 Achieves Co-Primary and Key Secondary Endpoints in MOMENTUM Phase 3 Migraine Trial in Patients with History of Inadequate Response
Watch Axsome Therapeutics' latest callAxsome Therapeutics (NASDAQ:AXSM) Q2 2026 Earnings Call · Replay · Aug 10Read the transcript of Axsome Therapeutics (NASDAQ:AXSM) Q2 2026 Earnings CallAxsome Therapeutics' next earnings callAxsome Therapeutics (NASDAQ:AXSM) Q3 2026 Earnings Call · Nov 2, 2026 at 8:00 AM ESTRegister
Axsome Therapeutics, Inc. on 6ix
In the deck
Earlier from Axsome Therapeutics
- Axsome Therapeutics Announces Closing of $200 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Axsome Therapeutics Announces Pricing of Public Offering of $174 Million of Shares of Common Stock
- Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in GEMINI Phase 3 Trial in Major Depressive Disorder
- Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in CONCERT Phase 2 Trial in Narcolepsy
- Axsome Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update
Later from Axsome Therapeutics
- Axsome Therapeutics Enters into Exclusive License Agreement with Pfizer Inc. for Pfizer’s Reboxetine Clinical and Nonclinical Data and for New Phase 3 Esreboxetine Product Candidate
- Axsome Therapeutics Completes Patient Randomization in the STRIDE-1 Phase 3 Trial of AXS-05 in Treatment Resistant Depression
- Axsome Therapeutics Completes Patient Enrollment in the INTERCEPT Phase 3 Trial of AXS-07 in the Early Treatment of Migraine
- Axsome Therapeutics Announces the Promotion of Mark Jacobson to Chief Operating Officer
- Axsome Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
Follow Axsome Therapeutics into a list and get an email when it puts out news.
Follow Axsome Therapeutics